Why Investors Shouldn’t Buy This 13%-Yielding Stock for Its Dividend

Dividend stocks offering investors high yields tend to be alluring because the income they generate for shareholders is better than average. However high yields often come with high risks. If a dividend proves to be unsustainable and a company slashes the payout, investors could be left holding a stock that suddenly doesn’t look all that great.

Medical Properties Trust (NYSE: MPW) pays investors a fairly high yield of 13% right now. That’s well above the S&P 500 average of just 1.4%. However, given the changes the company is undergoing right now, that dividend might not be the safest option for income investors.

Still, there are other potentially more enticing reasons to buy shares, provided you’re OK with the elevated risk.

Medical Properties Trust’s valuation is dirt cheap right now

Medical Properties Trust is a real estate investment trust (REIT) that focuses on hospitals. Ever since the start of the pandemic, it has been plagued with tenants struggling to pay rent, including Steward Health Care. The issue was concerning enough that at the start of the year, the REIT announced a plan to help Steward improve its liquidity and strengthen its balance sheet.

Because of these concerns, Medical Properties Trust hasn’t been a safe investment in recent years. That risk is evident in the stock’s price decline. Since 2021, the REIT’s valuation has plummeted close to 80%. Currently, the stock is trading at just 0.4 times its book value and a price-to-earnings multiple of less than 7. That big discount is what could make this a potentially attractive contrarian investment.

If Medical Properties Trust can turn things around, it could have tremendous upside

Medical Properties Trust is coming off a brutal 2023 during which it incurred a net loss of $556 million as a result of some hefty write-downs and impairment charges. That’s not something you expect to see from a REIT, which is normally a fairly safe investment since its main job is to collect rent from tenants.

If there aren’t any further impairment charges coming this year and the company is successful in helping Steward execute on a plan to improve liquidity, then there’s the potential for 2024 to be a much better year for the company.

It is also looking at selling assets that could add $2 billion to its own liquidity, as a way to add safety and stability. The drawback is that with fewer assets in its portfolio, the rent it generates might not be enough to support its current dividend, which could get another reduction (the REIT already reduced its dividend last year).

But if in the end, the asset sales and improved liquidity make the business a safer investment overall, that could make the REIT a better buy in the long run.

Should you take a chance on Medical Properties Trust?

This is not a REIT that is suitable for most dividend investors. The uncertainty on its payout means it can’t be relied on, and it could set you up for disappointment down the road.

If, however, you’re looking at Medical Properties Trust as a possible turnaround play and contrarian investment, and you’re comfortable with the high risk that comes with the stock, then that’s an angle that could make a lot more sense. If its turnaround plan is successful, then given its incredibly discounted valuation, the stock could generate significant returns.

Should you invest $1,000 in Medical Properties Trust right now?

Before you buy stock in Medical Properties Trust, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Medical Properties Trust wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.

See the 10 stocks

*Stock Advisor returns as of April 4, 2024

David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Why Investors Shouldn’t Buy This 13%-Yielding Stock for Its Dividend was originally published by The Motley Fool

Source link